Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | BACE1 | P56817 | 9/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8138593 | 0.90 | CTSS (0.59) | KLK7KLK5RENCTSSCTSK | |
| SCHEMBL12873043 | 0.90 | KLK7 (0.65) | KLK7KLK5MMEANPEPCTSS | |
| SCHEMBL17464243 | 0.90 | KLK7 (0.65) | KLK7KLK5MMEANPEPCTSS | |
| SCHEMBL11682562 | 0.89 | MME (0.59) | KLK7KLK5MMEANPEPREN | |
| SCHEMBL31372427 | 0.88 | PPARA (0.60) | KLK7KLK5CTSSCTSKPPARA | |
| SCHEMBL15569246 | 0.88 | PPARA (0.60) | KLK7KLK5CTSSCTSKPPARA | |
| SCHEMBL8138595 | 0.88 | PPARA (0.60) | KLK7KLK5CTSSCTSKPPARA | |
| SCHEMBL19388264 | 0.86 | BACE1 (0.61) | KLK7KLK5RENCTSSCTSK | |
| SCHEMBL21467154 | 0.86 | REN (0.64) | MMEANPEPRENBACE1BACE2 | |
| SCHEMBL6619713 | 0.85 | KLK7 (0.58) | KLK7KLK5MMEANPEPREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567489-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | disclosed |
| EP-1567489-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004052851-A1 | PYRROLYDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | TFPI, TFPI2, SERPINC1 | KLK7 310/4885KLK5 320/4885MME 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.